EUF Vol. 1 No. 1

FM4 96

e u r o p e a n u r o l o g y f o c u s , vo l . 1 , n o . 1 , Au g u s t 2 0 1 5
75
L.A. Kluth, E. Xylinas, M. Rieken, M. Kent, M. Ikeda, K. Matsumoto, M. Hagiwara, E. Kikuchi,
M.T. Bing, A. Gupta, J.M. Sewell, B.R. Konety, T. Todenhöfer, C. Schwentner, A. Masson-Lecomte,
D. Vordos, F. Roghmann, J. Noldus, A.A. Razmaria, N.D. Smith, E. Comploj, A. Pycha, M. Rink,
J. Baniel, R. Mano, G. Novara, A. Aziz, H.-M. Fritsche, A. Brisuda, T. Bivalacqua, P. Gontero,
S.A. Boorjian, A.J. Vickers, S.F. Shariat
We developed a model to predict survival after disease recurrence based on time to
disease recurrence and Karnofsky performance status.
82
R.T. Bryan, T. Evans, J.A. Dunn, G. Iqbal, S. Bathers, S.I. Collins, N.D. James, J.W.F. Catto,
D.M.A. Wallace
We can only advocate the timely treatment of patients with urothelial bladder
cancer (UBC). However, the relationship between delay and survival in UBC is
complex. Female patients present later than males, and our data suggest that this is
because of delay in referral.
90
A. Briganti, G. Giannarini
91
M. De Santis
92
R. Colombo
94
S.P. Lerner, J. Weinstein, D. Kwiatkowski, J. Kim, G. Robertson, K.A. Hoadley, R. Akbani,
C. Creighton, on behalf of the TCGA Muscle Invasive Bladder Cancer Analysis Working Group
The Cancer Genome Atlas project in bladder cancer reported the integrated
genomic analysis of the first 131 patients in 2014. This muscle-invasive cohort was
found to have one of the highest somatic mutation rates. The analysis working
group will reconvene in early 2015 to begin the final analysis.
Clinical Case
Discussions
Clinical Trial
Update
Original Articles
Bladder Cancer
The illustration on the cover (left-hand side) of this issue is taken from the article by
Alberto Briganti, Gianluca Giannarini, Case Presentation: A Man with Two Synchronous
and Symptomatic Malignancies Related to Smoking, which is published on pp. 90–91
of this issue.